Clinical Trial Update: A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 open-label trial of belantamab mafodotin in high-risk smoldering multiple myeloma is ongoing, with an extension cohort at a single center.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma | Phase 1 | Status: RECRUITING